Pharmacokinetics of desmopressin administrated as an oral lyophilisate dosage form in children with primary nocturnal enuresis and healthy adults

Journal of Clinical Pharmacology

Volumn 46, Issue 10, 2006, Pages 1204-1211

  Østerberg, Ole ^a   Savic, Radojka M ^b   Karlsson, Mats O ^b   Simonsson, Ulrika S H ^b   Nørgaard, Jens Peter ^a   Walle, Johan Vande ^c   Agersø, Henrik ^a  

^a Ferring Pharmaceuticals AS   (Denmark)

^b UPPSALA UNIVERSITY   (Sweden)

^c GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Desmopressin; Modeling; Pharmacokinetics; Primary nocturnal enuresis; Transit absorption model

Indexed keywords

DESMOPRESSIN;

ADULT; ARTICLE; CHILD; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG ELIMINATION; FEMALE; HUMAN; HUMAN EXPERIMENT; LYOPHILISATE; MAJOR CLINICAL STUDY; MALE; NOCTURNAL ENURESIS; NORMAL HUMAN;

ADMINISTRATION, SUBLINGUAL; ADOLESCENT; ADULT; AGE FACTORS; ALGORITHMS; ANTIDIURETIC AGENTS; BIOLOGICAL AVAILABILITY; CHILD; CROSS-OVER STUDIES; DEAMINO ARGININE VASOPRESSIN; DOSAGE FORMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FREEZE DRYING; HUMANS; INTESTINAL ABSORPTION; METABOLIC CLEARANCE RATE; MIDDLE AGED; MODELS, BIOLOGICAL; NOCTURNAL ENURESIS; TISSUE DISTRIBUTION;

EID: 33748643588     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270006291838     Document Type: Article

References (21)

1. Andersson KE, Arner B. Effects of DDAVP, A synthetic analogue of vasopressin, in patients with cranial diabetes insipidus. Acta Med Scand. 1972;192:21-27.
2. Robinson AG. DDAVP in the treatment of central diabetes insipidus. N Engl J Med. 1976;294:507-511.
3. Seif SM, Zenser TV, Ciarochi FF, Davis BB, Robinson AG. DDAVP (1-desamino-8-D-arginine-vasopressin) treatment of central diabetes insipidus - mechanism of prolonged antidiuresis. J Clin Endocrinol Metab. 1978;46:381-388.
4. Fjellestad-Paulsen A, Paulsen O, Gay-Abensour L, Lundin S, Czernichow P. Central diabetes insipidus: oral treatment with dDAVP. Regul Pept. 1993;45:303-307.
5. Birkasova M, Birkas O, Flynn MJ, Cort JH. Desmopressin in the management of nocturnal enuresis in children: a double-blind study. Pediatrics. 1978;62:970-974.
6. Fjellestad-Paulsen A, Tubiana-Rufi N, Harris A, Czernichow P. Central diabetes insipidus in children: antidiuretic effect and pharmacokinetics of intranasal and peroral 1-deamino-8-D-arginine vasopressin. Acta Endocrinol (Copenh). 1987;115:307-312.
7. Neveus T, Lackgren G, Tuvemo T, Stenberg A. Osmoregulation and desmopressin pharmacokinetics in enuretic children. Pediatrics. 1999;103:65-70.
8. Seager H. Drug-delivery products and the Zydis fast-dissolving dosage form. J Pharm Pharmacol. 1998;50:375-382.
9. Clarke A, Johnson ES, Mallard N, et al. A new low-dose formulation of selegiline: clinical efficacy, patient preference and selectivity for MAO-B inhibition. J Neural Transm. 2003;110:1257-1271.
10. Callreus T, Odeberg J, Lundin S, Hoglund P. Indirect-response modeling of desmopressin at different levels of hydration. J Pharmacokinet Biopharm. 1999;27:513-529.
11. Lundin S, Melin P, Vilhardt H. Plasma concentrations of 1-deamino-8-D-arginine vasopressin after intragastric administration in the rat. Acta Endocrinol (Copenh). 1985;108:179-183.
12. US Department of Health and Human Services Food and Drug Administration. Guidance for Industry Bioanalytical Method Validation. Rockville, Md: US Department of Health and Human Services Food and Drug Administration; 2001.
13. Turnheim D. The OECD Policy for the Implementation of the Principles of Good Laboratory Practice. Ann Ist Super Sanita. 1994;30:395-400.
14. Boeckmann AJ, Sheiner LB, Beal SL. NONMEM Users Guide. San Francisco, Calif: NONMEM Project Group, University of California, San Francisco; 2000. Ref Type: Generic.
15. Savic R, Jonker MD, Kerbusch T, Karlsson OM. Evaluation of a transit compartment model versus a lag time model for describing drug absorption delay. Oral presentation presented at: the Annual Meeting of the Population Approach Group in Europe; June 17, 2004; Uppsala, Sweden. Abstract 513. Available at: http://www.page-meeting.org/?abstract=513.
16. Jonsson EN, Karlsson MO. Xpose - an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed. 1999;58:51-64.
17. Lindbom L, Ribbing J, Jonsson EN. Perl-Speaks-NONMEM (Psn) - a Perl module for NONMEM related programming. Comput Methods Programs Biomed. 2004;75:85-94.
18. Agerso H, Seiding LL, Riis A, Lovgren U, Karlsson MO, Senderovitz T. Pharmacokinetics and renal excretion of desmopressin after intravenous administration to healthy subjects and renally impaired patients. Br J Clin Pharmacol. 2004;58:352-358.
19. Sadray S, Jonsson EN, Karlsson MO. Likelihood-based diagnostics for influential individuals in non-linear mixed effects model selection. Pharm Res. 1999;16:1260-1265.
20. Committee for Medicinal Products for Human Use. DRAFT Guideline on the Role of Pharmacokinetics in the Development of Medicinal Products in the Paediatric Population. European Medicines Agency; 2005 Feb 1. Report No: EMEA/CHMP/EWP/ 147013/2004.
21. Kerns GJ, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. Development pharmacology - drug disposition, action, and therapy in infants and children. N Engl J Med. 2003;349:1157-1167.